Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBITDA Margin for 1 consecutive years, with 58915.04% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 58915.04% in Q2 2025 year-over-year; TTM through Dec 2025 was 27.84%, a N/A change, with the full-year FY2025 number at 1.29%, changed N/A from a year prior.
  • EBITDA Margin was 58915.04% for Q2 2025 at Neuphoria Therapeutics, up from 73.78% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 58915.04% in Q2 2025 to a low of 73.78% in Q1 2025.